Date: 2014-11-10
Type of information: Series A financing round
Company: Histide (Switzerland)
Investors: PARTER Capital Group (Switzerland) and a group of private investors
Amount: CHF 4.5 Million (€3.7 million)
Funding type: series A financing round
Planned used: Histide will use thiese funds to advance its pioneering Recoding Therapeutics™ technology, a novel therapy using non-mutagenic extracellular technologies to direct cell fate. Based on the universal understanding of the mechanisms underlying mammalian cell behavior, Histide™ has created an innovative platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells. In contrast to previously developed gene therapies or RNA based therapies, the Histide™ technology has the major advantage of not requiring the introduction of foreign molecules inside the cell which in turn may be irreversibly harmful to its functioning. Recoding Therapeutics™ are instead an extracellular technological approach that promotes and stimulates the cell’s natural capacities to redirect its own fate by integrating accurate micro-environmental recoding signals. This allows for a precise and fine functional tuning that offers a master control over the cell biology. Recoding Therapeutics™ are the closest to the natural cell physiology, hence, providing significantly improved safety and efficacy. They have the potential to address a wide range of altered cell conditions and diseases through the regeneration of a large majority of the human body tissues. Histide™ has created a broad and disruptive intellectual property portfolio including Recoding Molecules™, Micro-environmental Design and Therapeutical Development being a technological break-through with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics.
Others: * On November 10,2014, Histide AG, a privately held Swiss biotech company pioneering a new class of non-mutagenic extracellular technology, Recoding Therapeutics™, has announced the closure of a series A financing round of CHF 4.5 Million to expand further its IP licensing pipeline and clinical development of its innovative Recoding Molecules™. The round was led by PARTER Capital Group AG, Switzerland, and a group of private investors.
Therapeutic area:
